Contemporary OB/GYN week in review: Paragard IUD, antenatal metformin, and more

Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, September 02 - Friday, September 06, 2024), and click each link to read and watch anything you may have missed.

CooperSurgical unveils new inserter for simplified Paragard IUD placement

CooperSurgical has announced the launch of a newly FDA-approved inserter designed for single-handed placement of Paragard, a hormone-free copper intrauterine device.

Data has indicated over 99% efficacy for Paragard for up to 10 years, making it a reliable, long-term contraceptive method. Among Paragard users aged 25 to 50 years, 91% reported satisfaction after at least 1 year of use in a market survey. The new inserter makes the placement process simpler without impacting efficacy.

Click here for the full article.

Antenatal metformin exposure not linked to adverse neurodevelopment

There is no association between in utero exposure to metformin and adverse neurodevelopmental outcomes in children aged up to 14 years, according to a recent study published in the American Journal of Obstetrics & Gynecology.

Studies including women who received metformin during pregnancy with follow-up results for neurodevelopmental outcomes were eligible for the analysis. Neurodevelopmental outcomes included intelligence based on assessments of intelligence quotient and motor, cognitive, and verbal outcomes defined using validated tools.

Neurodevelopmental outcomes in infants aged under 2 years were assessed in 3 studies, which reported a relative risk (RR) of 1.09 for global neurodevelopmental delay in infants with antenatal metformin exposure vs unexposed infants. This indicated no increased risk, and similar results were reported in children aged 3 to 5 years, with an RR of 0.90.

Click here for the full article.

Advisory committee meeting for oral sulopenem occurring September 9, 2024

On September 9, 2024, an advisory committee meeting will take place to discuss a new drug application for oral sulopenem etzadroxil/probenecid tablets.

The sulopenem tablets, which include 500 mg sulopenem etzadroxil and 500 mg probenecid, are being developed by Iterum Therapeutics US Ltd., to treat urinary tract infections linked to susceptible bacteria in women aged 18 years and older. The meeting will allow advisory committees to help the FDA come to a decision on the tablet’s approval.

Click here for the full article.

Study links solid organ transplant to adverse pregnancy outcomes

The risks of preeclampsia, preterm birth, and low birth weight are increased 4-fold to 6-fold among pregnancies receiving a solid organ transplant, according to a recent study published in JAMA Network Open.

Studies with participants who were pregnant and had solid organ transplants, as well as a comparison group of pregnant patients without solid organ transplant and at least 1 primary or secondary pregnancy outcome of interest were included in the analysis. Studies reporting allograft loss or allograft rejection during pregnancy were included for the second goal.

A significant association was reported between solid organ transplant and preeclampsia, with an odds ratio (OR) of 6.34 and adjusted odds ratio (aOR) of 6.34. Similarly, the OR and aOR for preterm birth after solid organ transplant were 7.48 and 5.31, respectively. Finally, for low birth weight, the OR and aOR were 5.50 and 4.96, respectively.

Click here for the full article.

HIV Roundtable: Adolescents and issues around care, adherence, and privacy

In this episode, the panel provides clinical feedback on the challenges for teens and young adults regarding staying in the continuum of care, adherence for PrEP, and potential adverse effects associated with it.
For adolescents who either are newly diagnosed with HIV or are trying to prevent contracting the virus, there are challenges around privacy.

“HIV care for a young person may be associated with forced disclosure around sex itself and sexuality, which may be really difficult depending on the family dynamic,” Ahokhai said. “I've been in some really, really challenging appointments with families around this very issue. I mean, heartbreakingly, so.”

Watch here.